Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...
UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals ... This is important because there’s a clear need to find non-addictive alternatives to opioid painkillers.
Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.
But the medication’s modest effectiveness and lengthy development process underscore the challenges of finding new ways to manage pain. Two studies in more than 870 patients with acute pain following ...
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...
Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results